Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeting Src in breast cancer.

R S Finn1

  • 1Department of Medicine, Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|May 20, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Regorafenib use in patients with unresectable hepatocellular carcinoma: analyses of subgroups of special interest in the observational REFINE study.

ESMO gastrointestinal oncology·2026
Same author

Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinoma.

ESMO open·2025
Same author

Effect of palbociclib plus letrozole on patient-reported health-related quality of life: extended follow-up of the PALOMA-2 trial.

ESMO open·2025
Same author

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up.

Breast cancer research and treatment·2019
Same author

Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer.

Investigational new drugs·2018
Same author

Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same journal

The ethical obligation to use positive trial results.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

Lorlatinib: The Crown Jewel of ALK Inhibitors.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

TROP2-Directed Antibody Drug Conjugates: New First-Line Treatment for All Patients with Advanced Triple-Negative Breast Cancer?

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

When artificial intelligence learns to abstain: towards clinically responsible diagnostic support in liver pathology.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

PRMT5 inhibitors in MTAP loss NSCLC with actionable genomic alterations: a new kid on the block?

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

Refining decision making in hormone receptor-positive early-stage breast cancer: moving from static to dynamic.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
See all related articles

Targeting Src kinase offers a promising therapeutic strategy for various cancers, particularly breast cancer. Inhibitors show potential, especially for triple-negative breast cancer with limited treatment options.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The success of targeted therapies validates blocking oncogenic pathways.
  • Src kinases are crucial for cancer cell growth, proliferation, angiogenesis, invasion, and metastasis.
  • Src kinase activity is implicated in bone resorption associated with bone metastases.

Purpose of the Study:

  • To review the rationale for targeting Src in breast cancer.
  • To discuss laboratory and clinical data supporting Src's role in cancer signaling.
  • To review small-molecule tyrosine kinase inhibitors targeting Src in clinical development.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of Src's role in cancer cell signaling pathways.

Related Experiment Videos

  • Evaluation of small-molecule tyrosine kinase inhibitors.

    • Main Results:

    • Src kinase plays a critical role in key cancer processes like proliferation and metastasis.
    • Blocking Src kinase is predicted to benefit patients with Src-dependent cancers.
    • Preclinical data suggest efficacy of Src inhibitors in triple-negative breast cancer.

    Conclusions:

    • Targeting Src kinase represents a significant therapeutic strategy in oncology.
    • Identifying patient populations for Src-directed therapies is crucial for clinical success.
    • Src inhibitors show particular promise for basal-type/triple-negative breast cancer.